INZ-701 targets a rare, serious, and progressive genetic condition that affects blood vessels, soft tissues and bones, with increased cardiovascular mortality risk and severe rickets/osteomalacia in children and adults. The ENERGY 3 pivotal trial for INZ-701 completed enrollment in January 2025, with topline data anticipated in Q1 2026. Analysts project peak annual sales of $400–$600 million by the mid-2030s.
Cyborg Score Rationale
The company demonstrates promising clinical progress with strong safety profiles and no patient dropouts in its pivotal trial. However, the imminent acquisition by BioMarin eliminates near-term stock upside, and regulatory approval remains dependent on Phase 3 data readout in Q1 2026. The company faces cash constraints with runway extending only to Q1 2026.
Top Insights
ENERGY 3 pivotal trial shows favorable safety profile with no dropouts or dose modifications and sustained phosphate increases, supporting INZ-701's potential to become the first approved therapy for ENPP1 Deficiency.
Phase 3 pivotal data readout in children expected in early 2026, with potential FDA approval in 2027, though the transaction is expected to close in Q3 2025.
Multiple law firms are investigating whether Inozyme's board breached fiduciary duty, with arguments that the $4.00/share price is below the 52-week high of $6.24 and undervalues the lead asset.
INZ-701 showed an 80% survival rate in infants beyond first year, reduced arterial calcifications, improved heart function, and no evidence of rickets in interim trial data.
Named Competitors
Enzyme Replacement Therapies — Acquirer of Inozyme; established enzyme therapy developer for rare genetic diseases
Recent Developments
(January 2025) ENERGY 3 pivotal trial enrollment completed with 25 pediatric patients; topline data expected Q1 2026
(May 2025) BioMarin Pharmaceutical announced definitive agreement to acquire Inozyme for $4.00/share ($270M total); transaction expected to close Q3 2025
(May 2025) Dr. Petra Duda appointed Chief Medical Officer; Q1 2025 results show $84.8M cash with runway into Q1 2026
(January 2025) Positive interim data released from ENERGY 1 trial showing 80% infant survival rate beyond first year with favorable safety profile
Open the full interactive Inozyme Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.